It will probably provide you with a sense of contrarian satisfaction to know that I strongly doubt that anyone in the neuropharm industry would concur with your conclusion that the anticipation of RD royalties in 2016 and onward would provide stronger value enhancement to Cortex's share price than anticipation of, and consummation of, an ADHD partnership in 2011--provided that they show good results in Phase IIa. That is the obvious but crucial caveat.
Market Data 
Markets 
AI
